This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Tianyin Pharmaceutical Co., Inc. (TPI)
F3Q 2011 Earnings Call
May 17, 2011 9:00 am ET
James Jiayuan Tong – Chief Financial Officer and Chief Business & Development Officer
Adam Waldo – Lismore Partners LLC
Angel Liu – Pope Asset Management
Iao Kiagra – Private Investor
Good morning ladies and gentlemen and thank you for standing by. Welcome to the Tianyin Pharmaceutical Incorporated FQ3 2011 Earnings Conference Call.
And at this time I would now like to turn the conference over to Dr. James Tong who is the Chief Financial Officer. Please go ahead sir.
James Jiayuan Tong
Thank you operator. Good morning, good evening ladies and gentlemen. Welcome to Tianyin Pharmaceutical TTI FQ3 2011 Earnings Conference Call. I am James Jiayuan Tong, Chief Financial Officer and Chief Business Development Officer of TTI along with Simon Min Ren, Director of Investor Relation and Meinian Yuan, Assistant to CFO. We haven’t connected with Dr. Guoqing, CEO and Chairman of the company because he is on the road at the moment and so far the signal connection has not been restored.
During this conference call we will be reviewing the FQ3 2011 financial highlights followed by the question and answer period. Before we continue please know that this call will contain forward-looking statements made under the Safe Harbor provisions of the US Private Security Litigation Reform Act of 1995.
Any statements set forth in this presentation, that are not historical facts or forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include but are not limited to such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, fluctuation in the economy, results of research and development, failure to obtain regulatory approvals and other information detailed from time to time in TPI’s filing and future filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this presentation are made only for this date and TPI’s under no obligation to revise or update these forward-looking statements.